Regarding the therapeutic agents, our study employed VEGF‐encoding Ad and NVs derived from bone marrow stromal cells.[31] While pro‐angiogenic gene therapy and stem cell therapy have shown promise in preventing heart failure post‐MI, the local retention of these agents in the infarcted myocardium remains a major challenge. This evidence concerns the gene VEGFA and heart failure.